Top

Published in:

Open Access 01-05-2020 | Liver Cirrhosis | Original Article

Pentraxin-3 is not related to disease severity in cirrhosis and hepatocellular carcinoma patients

Authors: Susanne Feder, Elisabeth M. Haberl, Marlen Spirk, Thomas S. Weiss, Reiner Wiest, Christa Buechler

Published in: Clinical and Experimental Medicine | Issue 2/2020

Abstract

The acute-phase protein pentraxin-3 (PTX3) is a component of the innate immune system. Inflammation and tissue injury increased PTX3 in the injured liver, and accordingly, circulating PTX3 was induced in patients with chronic liver diseases. In the present study, PTX3 protein was determined in systemic, hepatic, and portal vein plasma of patients with liver cirrhosis to assess a possible association between hepatic PTX3 release and extent of liver injury. However, PTX3 levels were not related to disease severity. Of note, portal PTX3 levels were higher than concentrations in the hepatic vein. PTX3 in the hepatic and portal veins was negatively correlated with factor V, antithrombin 3, and prothrombin time. PTX3 did neither correlate with C-reactive protein nor galectin-3 or resistin, whereby the latter two proteins are associated with hepatic injury. PTX3 levels were not changed in cirrhosis patients with ascites or varices and did not correlate with the hepatic venous pressure gradient. Likewise, serum PTX3 was not correlated with histological steatosis, inflammation, or fibrosis stage in patients with hepatocellular carcinoma (HCC). Moreover, PTX3 was not associated with tumor node metastasis classification in HCC. Above all, PTX3 increased in hepatic, portal, and systemic blood immediately after transjugular intrahepatic portosystemic shunt (TIPS). Higher PTX3 in portal than hepatic vein plasma and further increase after TIPS suggests that the liver eliminates PTX3 from the circulation. In summary, PTX3 is not of diagnostic value in cirrhosis and HCC patients.

Pinzani M, Rosselli M, Zuckermann M. Liver cirrhosis. Best Pract Res Clin Gastroenterol. 2011;25(2):281–90. https://doi.org/10.1016/j.bpg.2011.02.009.CrossRefPubMed

Nusrat S, Khan MS, Fazili J, Madhoun MF. Cirrhosis and its complications: evidence based treatment. World J Gastroenterol. 2014;20(18):5442–60. https://doi.org/10.3748/wjg.v20.i18.5442.CrossRefPubMedPubMedCentral

Laleman W, Landeghem L, Wilmer A, Fevery J, Nevens F. Portal hypertension: from pathophysiology to clinical practice. Liver Int. 2005;25(6):1079–90. https://doi.org/10.1111/j.1478-3231.2005.01163.x.CrossRefPubMed

Siramolpiwat S. Transjugular intrahepatic portosystemic shunts and portal hypertension-related complications. World J Gastroenterol. 2014;20(45):16996–7010. https://doi.org/10.3748/wjg.v20.i45.16996.CrossRefPubMedPubMedCentral

Basili S, Merli M, Ferro D, Lionetti R, Rossi E, Riggio O, et al. Clotting activation after transjugular intrahepatic portosystemic stent shunt. Thromb Haemost. 1999;81(5):711–4.CrossRef

De Santis A, Iegri C, Fagiuoli S. TIPS and HCC: friends or foes? Imaging Med. 2016;8:24–9.

Mantovani A, Garlanda C, Doni A, Bottazzi B. Pentraxins in innate immunity: from C-reactive protein to the long pentraxin PTX3. J Clin Immunol. 2008;28(1):1–13. https://doi.org/10.1007/s10875-007-9126-7.CrossRefPubMed

Pieri G, Agarwal B, Burroughs AK. C-reactive protein and bacterial infection in cirrhosis. Ann Gastroenterol. 2014;27(2):113–20.PubMedPubMedCentral

Erreni M, Manfredi AA, Garlanda C, Mantovani A, Rovere-Querini P. The long pentraxin PTX3: a prototypical sensor of tissue injury and a regulator of homeostasis. Immunol Rev. 2017;280(1):112–25. https://doi.org/10.1111/imr.12570.CrossRefPubMed

10.

Doni A, Musso T, Morone D, Bastone A, Zambelli V, Sironi M, et al. An acidic microenvironment sets the humoral pattern recognition molecule PTX3 in a tissue repair mode. J Exp Med. 2015;212(6):905–25. https://doi.org/10.1084/jem.20141268.CrossRefPubMedPubMedCentral

11.

Perea L, Coll M, Sanjurjo L, Blaya D, Taghdouini AE, Rodrigo-Torres D, et al. Pentraxin-3 modulates lipopolysaccharide-induced inflammatory response and attenuates liver injury. Hepatology. 2017;66(3):953–68. https://doi.org/10.1002/hep.29215.CrossRefPubMedPubMedCentral

12.

Jiao J, Friedman SL, Aloman C. Hepatic fibrosis. Curr Opin Gastroenterol. 2009;25(3):223–9.CrossRef

13.

Zanetti M, Bosutti A, Ferreira C, Vinci P, Biolo G, Fonda M, et al. Circulating pentraxin 3 levels are higher in metabolic syndrome with subclinical atherosclerosis: evidence for association with atherogenic lipid profile. Clin Exp Med. 2009;9(3):243–8. https://doi.org/10.1007/s10238-009-0039-z.CrossRefPubMed

14.

Bosutti A, Grassi G, Zanetti M, Aleksova A, Zecchin M, Sinagra G, et al. Relation between the plasma levels of LDL-cholesterol and the expression of the early marker of inflammation long pentraxin PTX3 and the stress response gene p66ShcA in pacemaker-implanted patients. Clin Exp Med. 2007;7(1):16–23. https://doi.org/10.1007/s10238-007-0118-y.CrossRefPubMed

15.

Trojak A, Walus-Miarka M, Kapusta M, Miarka P, Kawalec E, Idzior-Walus B, et al. Serum pentraxin 3 concentration in patients with type 2 diabetes and nonalcoholic fatty liver disease. Pol Arch Intern Med. 2019;129(7–8):499–505. https://doi.org/10.20452/pamw.14913.CrossRefPubMed

16.

Yoneda M, Uchiyama T, Kato S, Endo H, Fujita K, Yoneda K, et al. Plasma Pentraxin3 is a novel marker for nonalcoholic steatohepatitis (NASH). BMC Gastroenterol. 2008;8:53. https://doi.org/10.1186/1471-230X-8-53.CrossRefPubMedPubMedCentral

17.

Carmo RF, Aroucha D, Vasconcelos LR, Pereira LM, Moura P, Cavalcanti MS. Genetic variation in PTX3 and plasma levels associated with hepatocellular carcinoma in patients with HCV. J Viral Hepat. 2016;23(2):116–22. https://doi.org/10.1111/jvh.12472.CrossRefPubMed

18.

Gorka-Dynysiewicz J, Pazgan-Simon M, Zuwala-Jagiello J. Accurate prediction of significant liver fibrosis using the Pentra score model in patients with chronic hepatitis C. Pol Arch Intern Med. 2020. https://doi.org/10.20452/pamw.15134.CrossRefPubMed

19.

Song T, Wang C, Guo C, Liu Q, Zheng X. Pentraxin 3 overexpression accelerated tumor metastasis and indicated poor prognosis in hepatocellular carcinoma via driving epithelial-mesenchymal transition. J Cancer. 2018;9(15):2650–8. https://doi.org/10.7150/jca.25188.CrossRefPubMedPubMedCentral

20.

Fan WC, Huang CC, Yang YY, Lin A, Lee KC, Hsieh YC, et al. Serum pentraxin-3 and tumor necrosis factor-like weak inducer of apoptosis (TWEAK) predict severity of infections in acute decompensated cirrhotic patients. J Microbiol Immunol Infect. 2017;50(6):905–14. https://doi.org/10.1016/j.jmii.2015.12.006.CrossRefPubMed

21.

Narciso-Schiavon JL, Pereira JG, Silva TE, Bansho ETO, Morato EF, Pinheiro JT, et al. Circulating levels of pentraxin-3 (PTX3) in patients with liver cirrhosis. Ann Hepatol. 2017;16(5):780–7. https://doi.org/10.5604/01.3001.0010.2789.CrossRefPubMed

22.

Magrini E, Mantovani A, Garlanda C. The dual complexity of PTX3 in health and disease: a balancing act? Trends Mol Med. 2016;22(6):497–510. https://doi.org/10.1016/j.molmed.2016.04.007.CrossRefPubMedPubMedCentral

23.

Xu F, Jin T, Zhu Y, Dai C. Immune checkpoint therapy in liver cancer. J Exp Clin Cancer Res. 2018;37(1):110. https://doi.org/10.1186/s13046-018-0777-4.CrossRefPubMedPubMedCentral

24.

De Re V, Caggiari L, De Zorzi M, Repetto O, Zignego AL, Izzo F, et al. Genetic diversity of the KIR/HLA system and susceptibility to hepatitis C virus-related diseases. PLoS ONE. 2015;10(2):e0117420. https://doi.org/10.1371/journal.pone.0117420.CrossRefPubMedPubMedCentral

25.

Legrand AJ, Poletto M, Pankova D, Clementi E, Moore J, Castro-Giner F, et al. Persistent DNA strand breaks induce a CAF-like phenotype in normal fibroblasts. Oncotarget. 2018;9(17):13666–81. https://doi.org/10.18632/oncotarget.24446.CrossRefPubMedPubMedCentral

26.

Rossle M, Gerbes AL. TIPS for the treatment of refractory ascites, hepatorenal syndrome and hepatic hydrothorax: a critical update. Gut. 2010;59(7):988–1000. https://doi.org/10.1136/gut.2009.193227.CrossRefPubMed

27.

Eisinger K, Krautbauer S, Wiest R, Karrasch T, Hader Y, Scherer MN, et al. Portal vein omentin is increased in patients with liver cirrhosis but is not associated with complications of portal hypertension. Eur J Clin Invest. 2013;43(9):926–32. https://doi.org/10.1111/eci.12122.CrossRefPubMed

28.

Wanninger J, Weigert J, Wiest R, Bauer S, Karrasch T, Farkas S, et al. Systemic and hepatic vein galectin-3 are increased in patients with alcoholic liver cirrhosis and negatively correlate with liver function. Cytokine. 2011;55(3):435–40. https://doi.org/10.1016/j.cyto.2011.06.001.CrossRefPubMed

29.

Feder S, Kandulski A, Schacherer D, Weiss TS, Buechler C. Serum chemerin does not differentiate colorectal liver metastases from hepatocellular carcinoma. Int J Mol Sci. 2019;20(16):3919. https://doi.org/10.3390/ijms20163919.CrossRefPubMedCentral

30.

Witasp A, Carrero JJ, Michaelsson K, Ahlstrom H, Kullberg J, Adamsson V, et al. Inflammatory biomarker pentraxin 3 (PTX3) in relation to obesity, body fat depots and weight loss. Obesity (Silver Spring). 2014;22(5):1373–9. https://doi.org/10.1002/oby.20695.CrossRef

31.

Thomsson O, Strom-Holst B, Sjunnesson Y, Bergqvist AS. Validation of an enzyme-linked immunosorbent assay developed for measuring cortisol concentration in human saliva and serum for its applicability to analyze cortisol in pig saliva. Acta Vet Scand. 2014;56:55. https://doi.org/10.1186/s13028-014-0055-1.CrossRefPubMedPubMedCentral

32.

Andreasson U, Perret-Liaudet A, van Waalwijk van Doorn LJ, Blennow K, Chiasserini D, Engelborghs S, et al. A practical guide to immunoassay method validation. Front Neurol. 2015;6:179. https://doi.org/10.3389/fneur.2015.00179.CrossRefPubMedPubMedCentral

33.

Wiest R, Leidl F, Kopp A, Weigert J, Neumeier M, Buechler C, et al. Peritoneal fluid adipokines: ready for prime time? Eur J Clin Invest. 2009;39(3):219–29. https://doi.org/10.1111/j.1365-2362.2009.02085.x.CrossRefPubMed

34.

Tacke F, Weiskirchen R. An update on the recent advances in antifibrotic therapy. Expert Rev Gastroenterol Hepatol. 2018;12(11):1143–52. https://doi.org/10.1080/17474124.2018.1530110.CrossRefPubMed

35.

Buechler C, Haberl EM, Rein-Fischboeck L, Aslanidis C. Adipokines in Liver Cirrhosis. Int J Mol Sci. 2017;18(7):1392. https://doi.org/10.3390/ijms18071392.CrossRefPubMedCentral

36.

Wadhawan M, Dubey S, Sharma BC, Sarin SK. Hepatic venous pressure gradient in cirrhosis: correlation with the size of varices, bleeding, ascites, and child’s status. Dig Dis Sci. 2006;51(12):2264–9. https://doi.org/10.1007/s10620-006-9310-2.CrossRefPubMed

37.

Graham C, Chooniedass R, Stefura WP, Lotoski L, Lopez P, Befus AD, et al. Stability of pro- and anti-inflammatory immune biomarkers for human cohort studies. J Transl Med. 2017;15(1):53. https://doi.org/10.1186/s12967-017-1154-3.CrossRefPubMedPubMedCentral

38.

Napoleone E, Di Santo A, Bastone A, Peri G, Mantovani A, de Gaetano G, et al. Long pentraxin PTX3 upregulates tissue factor expression in human endothelial cells: a novel link between vascular inflammation and clotting activation. Arterioscler Thromb Vasc Biol. 2002;22(5):782–7.CrossRef

39.

Napoleone E, di Santo A, Peri G, Mantovani A, de Gaetano G, Donati MB, et al. The long pentraxin PTX3 up-regulates tissue factor in activated monocytes: another link between inflammation and clotting activation. J Leukoc Biol. 2004;76(1):203–9. https://doi.org/10.1189/jlb.1003528.CrossRefPubMed

40.

Kremers RMW, Kleinegris MC, Ninivaggi M, de Laat B, Ten Cate H, Koek GH, et al. Decreased prothrombin conversion and reduced thrombin inactivation explain rebalanced thrombin generation in liver cirrhosis. PLoS ONE. 2017;12(5):e0177020. https://doi.org/10.1371/journal.pone.0177020.CrossRefPubMedPubMedCentral

41.

Laine OK, Koskela SM, Outinen TK, Joutsi-Korhonen L, Huhtala H, Vaheri A, et al. Plasma pentraxin-3 and coagulation and fibrinolysis variables during acute Puumala hantavirus infection and associated thrombocytopenia. Blood Coagul Fibrinolysis: Int J Haemost Thrombosis. 2014;25(6):612–7. https://doi.org/10.1097/MBC.0000000000000117.CrossRef

42.

Boij R, Svensson J, Nilsson-Ekdahl K, Sandholm K, Lindahl TL, Palonek E, et al. Biomarkers of coagulation, inflammation, and angiogenesis are independently associated with preeclampsia. Am J Reprod Immunol. 2012;68(3):258–70. https://doi.org/10.1111/j.1600-0897.2012.01158.x.CrossRefPubMed

43.

Nur E, van Beers EJ, Martina S, Cuccovillo I, Otten HM, Schnog JJ, et al. Plasma levels of pentraxin-3, an acute phase protein, are increased during sickle cell painful crisis. Blood Cells Mol Dis. 2011;46(3):189–94. https://doi.org/10.1016/j.bcmd.2010.10.016.CrossRefPubMed

44.

Valente MJ, Rocha S, Coimbra S, Catarino C, Rocha-Pereira P, Bronze-da-Rocha E, et al. Long pentraxin 3 as a broader biomarker for multiple risk factors in end-stage renal disease: association with all-cause mortality. Mediat Inflamm. 2019;2019:3295725. https://doi.org/10.1155/2019/3295725.CrossRef

45.

Wiest R, Lawson M, Geuking M. Pathological bacterial translocation in liver cirrhosis. J Hepatol. 2014;60(1):197–209. https://doi.org/10.1016/j.jhep.2013.07.044.CrossRefPubMed

Title: Pentraxin-3 is not related to disease severity in cirrhosis and hepatocellular carcinoma patients
Authors: Susanne Feder
Elisabeth M. Haberl
Marlen Spirk
Thomas S. Weiss
Reiner Wiest
Christa Buechler
Publication date: 01-05-2020
Publisher: Springer International Publishing
Keywords: Liver Cirrhosis
Hepatocellular Carcinoma
Ascites
Hepatocellular Carcinoma
Published in: Clinical and Experimental Medicine / Issue 2/2020
Print ISSN: 1591-8890
Electronic ISSN: 1591-9528
DOI: https://doi.org/10.1007/s10238-020-00617-4

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Pentraxin-3 is not related to disease severity in cirrhosis and hepatocellular carcinoma patients

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2020

Systemic treatment of the metastatic renal cell carcinoma: usefulness of the apparent diffusion coefficient of diffusion-weighted MRI in prediction of early therapeutic response

Correction to: BAL biomarkers’ panel for differential diagnosis of interstitial lung diseases

MUC4 isoforms expression profiling and prognosis value in Chinese melanoma patients

Patient-derived xenograft models for personalized medicine in colorectal cancer

Prognostic significance of serum progranulin level in de novo adult acute lymphoblastic leukemia patients

BAL biomarkers’ panel for differential diagnosis of interstitial lung diseases

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page